Evaluation of the Safety and Efficacy of Pancrecarb® MS-16 in Cystic Fibrosis
Status:
Completed
Trial end date:
2007-09-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to determine if PANCRECARB® MS-16 (pancrelipase) is
safe and effective in reducing steatorrhea (as measured by 72-hour stool fat determinations)
in children and adults with cystic fibrosis and pancreatic insufficiency.